Inhibikase Therapeutics, Inc. (IKT)
- Previous Close
1.8600 - Open
1.6700 - Bid --
- Ask --
- Day's Range
1.6700 - 1.8110 - 52 Week Range
0.7900 - 4.3500 - Volume
98,979 - Avg. Volume
103,828 - Market Cap (intraday)
11.075M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-3.5700 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.50
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
www.inhibikase.comRecent News: IKT
Performance Overview: IKT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IKT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IKT
Valuation Measures
Market Cap
11.08M
Enterprise Value
-1.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.67%
Return on Equity (ttm)
-118.88%
Revenue (ttm)
260.5k
Net Income Avi to Common (ttm)
-19.03M
Diluted EPS (ttm)
-3.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
13.25M
Total Debt/Equity (mrq)
5.67%
Levered Free Cash Flow (ttm)
-12.17M